<p>政府债券收益率正在上升，通胀压力依然顽固，能源和地缘政治因素使市场保持紧张。在这种利率驱动的市场中，投资者通常会寻找在波动条件下能够保持稳定的股票。这就是低风险领导者筛选器的作用所在。它专注于具有更强资产负债表和较低模型风险评分的公司。旨在帮助您在不放弃回报潜力的情况下，构建更坚固的投资组合核心。在本文中，您将看到来自该筛选器的三只符合低风险、抗压特征的股票。</p>
<h2>Citizens Financial Group (CFG)</h2>
<p><strong>概述：</strong> Citizens Financial Group 是一家美国银行，提供全方位的消费和商业银行服务，从日常存款、抵押贷款、信用卡和财富管理，到企业贷款、资本市场咨询和企业及机构的风险管理解决方案。</p>
<p><strong>运营：</strong> Citizens 从消费银行业务中产生约 60 亿美元的收入，从商业银行业务中产生约 25 亿美元，总收入约为 79 亿美元，来自美国客户。</p>
<p><strong>市值：</strong> 259 亿美元</p>
<p>Citizens Financial Group 在低风险筛选中脱颖而出，因为它将对信用质量和资本实力的关注与盈利和效率的明确杠杆结合在一起。该银行通过其 “重新构想银行” 计划，积极投入人工智能和自动化，目标是实现数亿美元的税前效率，而其快速增长的私人银行业务已经贡献了约 10% 的税前收入，存款超过 160 亿美元。当前市盈率接近同行。您需要权衡的关键问题是，商业房地产的风险敞口和区域集中度是否会在周期演变中抵消这些优势。</p>
<p>Citizens 在人工智能驱动的效率提升和不断增长的私人银行业务方面的努力，可能掩盖了盈利质量的更大变化，因此请将这个故事与 Citizens Financial Group 的完整估值图景进行权衡，使用 DCF 估值分析。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4e00a58a-add4-487b-bb12-144763c93888/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTE2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1706" height="760" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4e00a58a-add4-487b-bb12-144763c93888/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTE2"/></p>
<p>截至 2026 年 5 月的 CFG 折现现金流</p>
<h2>United Therapeutics (UTHR)</h2>
<p><strong>概述：</strong> United Therapeutics 是一家生物技术公司，开发和销售用于治疗严重心肺疾病的疗法，如肺动脉高压和特发性肺纤维化。它还在研究下一代器官和组织技术，包括异种移植和再生医学平台。</p>
<p><strong>运营：</strong> United Therapeutics 从制药业务中产生约 32 亿美元的收入，其中约 30 亿美元来自美国客户，约 1.38 亿美元来自世界其他地区。</p>
<p><strong>市值：</strong> 244 亿美元</p>
<p>United Therapeutics 位于高利润专科药物与长期关注器官和组织技术的交汇点，Tyvaso 系列得到 IPF 数据的支持，产品线从 ralinepag 扩展到基因编辑器官如 UHeart。稳健的资产负债表和可观的回购能力使其有空间继续资助研发，同时向股东返还现金。该公司仍面临风险，包括对肺部疾病的集中暴露、巨额的试验和研发支出，以及如果关键项目遇到挫折，可能面临的药物定价压力。对于评估低风险领导者的投资者来说，关键考虑是相对于已建立的肺部业务，如何看待新兴的器官平台的重要性。</p>
<p>United Therapeutics 的器官技术故事可能正在悄然重塑肺部药物业务的估值，但大多数关注仍集中在现有疗法上。请查看 United Therapeutics 的分析师预测，以获取完整背景，了解可能被忽视的内容。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f0981ea6-8c55-4492-9a4c-3acc364f2deb/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTA1LTE2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f0981ea6-8c55-4492-9a4c-3acc364f2deb/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTA1LTE2"/></p>
<p>NasdaqGS:UTHR 截至 2026 年 5 月的收益与收入增长</p>
<h2>Palantir Technologies (PLTR)</h2>
<p><strong>概述：</strong> Palantir Technologies 构建软件平台，帮助政府和公司整合大量数据，发现模式，并在国防、安全和运营等领域支持实时决策。</p>
<p><strong>运营：</strong> Palantir 从政府客户中产生约 28 亿美元的收入，从商业客户中产生约 25 亿美元，约 40 亿美元来自美国，约 4.678 亿美元来自英国，约 7.827 亿美元来自世界其他地区。</p>
<p><strong>市值：</strong> 3206 亿美元</p>
<p>Palantir 位于政府和企业人工智能采用的中心，拥有高利润的软件，已经嵌入到关键的美国国防项目中，并通过 SAP、埃森哲、斯特兰蒂斯和 LG CNS 等合作伙伴进行大规模商业推广。预计收益和收入每年都将增长超过 29%，盈利能力目前强劲。然而，该股票的市盈率非常高，因此即使是小的失望或人工智能竞争的加剧也可能引发剧烈波动。此外，关于数据使用的监管审查和近期的内部人士抛售，造成了复杂的风险回报局面，许多投资者仍然只部分考虑这些因素。</p>
<p>Palantir 的人工智能故事和高市盈率表明，市场可能在定价明显的东西，而不是下一个章节。考虑使用 Palantir Technologies 的分析师预测来压力测试该增长与估值的权衡。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f8e4a674-51cb-4764-b739-5058e13a50ef/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTA1LTE2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f8e4a674-51cb-4764-b739-5058e13a50ef/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTA1LTE2"/></p>
<p>NasdaqGS:PLTR 截至 2026 年 5 月的收益与收入增长</p>
<p>您刚刚看到的三只股票只是这个想法的一个小样本，完整的低风险领导者筛选器还显示出 63 家公司，每家公司都有其自身的抗压资产负债表和较低的模型风险。使用 Simply Wall St 识别和分析对您重要的具体催化剂和叙事，以便您能够专注于最适合您投资组合的机会。</p>
<h2>掌控您的投资旅程</h2>
<p>如果联合治疗公司或这些公司引起了您的关注，请免费注册 Simply Wall St，并将您的公司添加到观察列表中，以监控股价与公允价值的对比，并跟踪任何新动态。一旦您采取行动，使用我们的投资组合指挥中心管理您的持股，该中心过滤掉噪音，仅提供最关键、可操作的更新。在您的旅程中，我们的社区允许您从成千上万的投资者观点中筛选出最佳想法。通过及早发现隐藏的催化剂和风险，您将加快决策速度，始终领先于市场。</p>
<h2>在别人注意到之前寻找新选择？</h2>
<p>市场变化迅速，最佳的投资机会很少会保持安静。为了发现新的动能、潜在的突破以及目前仍在雷达下飞行的股票，请考虑在条件仍然有利时采取行动。</p>
<ul>
<li>通过扫描一份经过筛选的稳健资产负债表和基本面（45 个结果），跟踪有成长空间的稳健盈利者，帮助您在裂痕显现之前避免脆弱的故事。</li>
<li>通过关注 34 只精英黄金生产股票，跟踪金属生产商的早期强劲表现，这些股票可能在市场情绪转向硬资产时作出反应。</li>
<li>使用一组 22 只高质量未被发现的潜力股，监控那些尚未被市场广泛评估现金流和资产负债表质量的低调运营商。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
<h3><strong>新功能：在一个地方管理您的所有股票投资组合</strong></h3>
<p>我们为股票投资者创建了 <strong>终极投资组合伴侣</strong>，<strong>而且是免费的。</strong></p>
<p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
<p>• 通过电子邮件或手机接收新的警告信号或风险提示</p>
<p>• 跟踪您股票的公允价值</p>
<p>免费试用演示投资组合</p>

联合治疗

PLTR

2 倍做多 Palantir ETF - Direxion

<p>在动荡的市场中，投资者正转向低风险股票。本文重点介绍了三家公司：公民金融集团（Citizens Financial Group），一家专注于人工智能和效率的美国银行；联合治疗（United Therapeutics），一家开发肺部疾病治疗方案的生物技术公司；以及帕兰提尔科技（Palantir Technologies），为国防和商业领域提供数据软件的公司。每家公司都显示出强劲的收入潜力，但面临独特的风险，包括市场竞争和监管审查。投资者应权衡这些因素与增长预测和估值</p>

<p>Government bond yields are climbing, inflation pressures are sticky, and energy and geopolitics are keeping markets on edge. In this kind of rate driven market, investors often look for stocks that can hold up when conditions are choppy. That is where the Low-Risk Leaders screener comes in. It focuses on companies with stronger balance sheets and lower model risk scores. It is designed to help you build a sturdier core in your portfolio without walking away from return potential. In this article, you will see 3 stocks from this screener that fit that low risk, resilient profile.</p>
<div class="lb-trans"><p>政府债券收益率正在上升，通胀压力依然顽固，能源和地缘政治因素使市场保持紧张。在这种利率驱动的市场中，投资者通常会寻找在波动条件下能够保持稳定的股票。这就是低风险领导者筛选器的作用所在。它专注于具有更强资产负债表和较低模型风险评分的公司。旨在帮助您在不放弃回报潜力的情况下，构建更坚固的投资组合核心。在本文中，您将看到来自该筛选器的三只符合低风险、抗压特征的股票。</p>
</div><h2>Citizens Financial Group (CFG)</h2>
<div class="lb-trans"><h2>Citizens Financial Group (CFG)</h2>
</div><p><strong>Overview:</strong> Citizens Financial Group is a US bank that provides a full range of consumer and commercial banking services, from everyday deposits, mortgages, cards, and wealth management to corporate lending, capital markets advice, and risk management solutions for businesses and institutions.</p>
<div class="lb-trans"><p><strong>概述：</strong> Citizens Financial Group 是一家美国银行，提供全方位的消费和商业银行服务，从日常存款、抵押贷款、信用卡和财富管理，到企业贷款、资本市场咨询和企业及机构的风险管理解决方案。</p>
</div><p><strong>Operations:</strong> Citizens generates about US$6.0b of revenue from Consumer Banking and US$2.5b from Commercial Banking, with total revenue of roughly US$7.9b coming from customers in the United States.</p>
<div class="lb-trans"><p><strong>运营：</strong> Citizens 从消费银行业务中产生约 60 亿美元的收入，从商业银行业务中产生约 25 亿美元，总收入约为 79 亿美元，来自美国客户。</p>
</div><p><strong>Market Cap:</strong> US$25.9b</p>
<div class="lb-trans"><p><strong>市值：</strong> 259 亿美元</p>
</div><p>Citizens Financial Group stands out in a low risk screen because it combines a focus on credit quality and capital strength with clear levers for earnings and efficiency. The bank is leaning into AI and automation through its Reimagine the Bank program, targeting hundreds of millions of dollars in pretax efficiencies, while its fast growing private bank already contributes around 10% of pretax income on more than US$16b of deposits. The P/E currently sits close to peers. The key tension for you to weigh is whether commercial real estate exposure and regional concentration could offset these strengths as the cycle evolves.</p>
<div class="lb-trans"><p>Citizens Financial Group 在低风险筛选中脱颖而出，因为它将对信用质量和资本实力的关注与盈利和效率的明确杠杆结合在一起。该银行通过其 “重新构想银行” 计划，积极投入人工智能和自动化，目标是实现数亿美元的税前效率，而其快速增长的私人银行业务已经贡献了约 10% 的税前收入，存款超过 160 亿美元。当前市盈率接近同行。您需要权衡的关键问题是，商业房地产的风险敞口和区域集中度是否会在周期演变中抵消这些优势。</p>
</div><p>Citizens’ push into AI driven efficiency and a growing private bank could be masking a much bigger shift in earnings quality, so weigh that story against the full valuation picture with the DCF valuation analysis for Citizens Financial Group.</p>
<div class="lb-trans"><p>Citizens 在人工智能驱动的效率提升和不断增长的私人银行业务方面的努力，可能掩盖了盈利质量的更大变化，因此请将这个故事与 Citizens Financial Group 的完整估值图景进行权衡，使用 DCF 估值分析。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4e00a58a-add4-487b-bb12-144763c93888/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTE2" alt="" original-src="https://images.simplywall.st/company/4e00a58a-add4-487b-bb12-144763c93888/chart/dcf?date=2026-05-16"/></p>
<p>CFG Discounted Cash Flow as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月的 CFG 折现现金流</p>
</div><h2>United Therapeutics (UTHR)</h2>
<div class="lb-trans"><h2>United Therapeutics (UTHR)</h2>
</div><p><strong>Overview:</strong> United Therapeutics is a biotechnology company that develops and sells therapies for serious cardiopulmonary conditions such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. It is also working on next generation organ and tissue technologies, including xenotransplantation and regenerative medicine platforms.</p>
<div class="lb-trans"><p><strong>概述：</strong> United Therapeutics 是一家生物技术公司，开发和销售用于治疗严重心肺疾病的疗法，如肺动脉高压和特发性肺纤维化。它还在研究下一代器官和组织技术，包括异种移植和再生医学平台。</p>
</div><p><strong>Operations:</strong> United Therapeutics generates about US$3.2b of revenue from pharmaceuticals, with roughly US$3.0b from customers in the United States and about US$138m from the rest of the world.</p>
<div class="lb-trans"><p><strong>运营：</strong> United Therapeutics 从制药业务中产生约 32 亿美元的收入，其中约 30 亿美元来自美国客户，约 1.38 亿美元来自世界其他地区。</p>
</div><p><strong>Market Cap:</strong> US$24.4b</p>
<div class="lb-trans"><p><strong>市值：</strong> 244 亿美元</p>
</div><p>United Therapeutics sits at the intersection of high margin specialty drugs and a long term focus on organ and tissue technologies, with a Tyvaso franchise supported by IPF data and a pipeline that extends from ralinepag to gene edited organs such as UHeart. A solid balance sheet and sizeable buyback capacity give it room to continue funding R&amp;D while returning cash to shareholders. The company still faces risks, including concentrated exposure to pulmonary diseases, substantial trial and R&amp;D spending, and potential drug pricing pressure if key programs face setbacks. For investors assessing lower risk leaders, a key consideration is how much importance to place on the emerging organ platform relative to the established pulmonary business.</p>
<div class="lb-trans"><p>United Therapeutics 位于高利润专科药物与长期关注器官和组织技术的交汇点，Tyvaso 系列得到 IPF 数据的支持，产品线从 ralinepag 扩展到基因编辑器官如 UHeart。稳健的资产负债表和可观的回购能力使其有空间继续资助研发，同时向股东返还现金。该公司仍面临风险，包括对肺部疾病的集中暴露、巨额的试验和研发支出，以及如果关键项目遇到挫折，可能面临的药物定价压力。对于评估低风险领导者的投资者来说，关键考虑是相对于已建立的肺部业务，如何看待新兴的器官平台的重要性。</p>
</div><p>United Therapeutics’ organ technology story could be quietly reshaping how the pulmonary drug business is valued, yet most focus still sits on existing therapies. Get the full context in the analyst forecasts for United Therapeutics to see what might be missing.</p>
<div class="lb-trans"><p>United Therapeutics 的器官技术故事可能正在悄然重塑肺部药物业务的估值，但大多数关注仍集中在现有疗法上。请查看 United Therapeutics 的分析师预测，以获取完整背景，了解可能被忽视的内容。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f0981ea6-8c55-4492-9a4c-3acc364f2deb/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTA1LTE2" alt="" original-src="https://images.simplywall.st/company/f0981ea6-8c55-4492-9a4c-3acc364f2deb/chart/earnings-and-revenue-growth?date=2026-05-16"/></p>
<p>NasdaqGS:UTHR Earnings &amp; Revenue Growth as at May 2026</p>
<div class="lb-trans"><p>NasdaqGS:UTHR 截至 2026 年 5 月的收益与收入增长</p>
</div><h2>Palantir Technologies (PLTR)</h2>
<div class="lb-trans"><h2>Palantir Technologies (PLTR)</h2>
</div><p><strong>Overview:</strong> Palantir Technologies builds software platforms that help governments and companies pull together huge amounts of data, spot patterns, and support real time decisions in areas like defense, security, and operations.</p>
<div class="lb-trans"><p><strong>概述：</strong> Palantir Technologies 构建软件平台，帮助政府和公司整合大量数据，发现模式，并在国防、安全和运营等领域支持实时决策。</p>
</div><p><strong>Operations:</strong> Palantir generates about US$2.8b from Government customers and US$2.5b from Commercial customers, with roughly US$4.0b coming from the United States, US$467.8m from the United Kingdom, and US$782.7m from the rest of the world.</p>
<div class="lb-trans"><p><strong>运营：</strong> Palantir 从政府客户中产生约 28 亿美元的收入，从商业客户中产生约 25 亿美元，约 40 亿美元来自美国，约 4.678 亿美元来自英国，约 7.827 亿美元来自世界其他地区。</p>
</div><p><strong>Market Cap:</strong> US$320.6b</p>
<div class="lb-trans"><p><strong>市值：</strong> 3206 亿美元</p>
</div><p>Palantir sits at the center of government and enterprise AI adoption, with high margin software that is already embedded in critical US defense programs and large commercial rollouts through partners such as SAP, Accenture, Stellantis, and LG CNS. Earnings and revenue are both forecast to grow more than 29% a year, and profitability is currently strong. However, the stock trades on a very rich P/E, so even minor disappointments or rising competition in AI could trigger sharp swings. In addition, regulatory scrutiny around data use and recent insider selling create a complex risk reward setup that many investors are still only partly factoring in.</p>
<div class="lb-trans"><p>Palantir 位于政府和企业人工智能采用的中心，拥有高利润的软件，已经嵌入到关键的美国国防项目中，并通过 SAP、埃森哲、斯特兰蒂斯和 LG CNS 等合作伙伴进行大规模商业推广。预计收益和收入每年都将增长超过 29%，盈利能力目前强劲。然而，该股票的市盈率非常高，因此即使是小的失望或人工智能竞争的加剧也可能引发剧烈波动。此外，关于数据使用的监管审查和近期的内部人士抛售，造成了复杂的风险回报局面，许多投资者仍然只部分考虑这些因素。</p>
</div><p>Palantir’s AI story and rich P/E suggest the market may be pricing the obvious rather than the next chapter. Consider pressure testing that growth versus valuation trade off with the analyst forecasts for Palantir Technologies.</p>
<div class="lb-trans"><p>Palantir 的人工智能故事和高市盈率表明，市场可能在定价明显的东西，而不是下一个章节。考虑使用 Palantir Technologies 的分析师预测来压力测试该增长与估值的权衡。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f8e4a674-51cb-4764-b739-5058e13a50ef/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTA1LTE2" alt="" original-src="https://images.simplywall.st/company/f8e4a674-51cb-4764-b739-5058e13a50ef/chart/earnings-and-revenue-growth?date=2026-05-16"/></p>
<p>NasdaqGS:PLTR Earnings &amp; Revenue Growth as at May 2026</p>
<div class="lb-trans"><p>NasdaqGS:PLTR 截至 2026 年 5 月的收益与收入增长</p>
</div><p>The three stocks you have just seen are only a small sample of what this idea turns up, with the full Low-Risk Leaders screen surfacing 63 more companies in the Low-Risk Leaders screener that each have their own case for resilient balance sheets and lower model risk. Use Simply Wall St to identify and analyze the specific catalysts and narratives that matter to you so you can focus on the opportunities that best fit your portfolio.</p>
<div class="lb-trans"><p>您刚刚看到的三只股票只是这个想法的一个小样本，完整的低风险领导者筛选器还显示出 63 家公司，每家公司都有其自身的抗压资产负债表和较低的模型风险。使用 Simply Wall St 识别和分析对您重要的具体催化剂和叙事，以便您能够专注于最适合您投资组合的机会。</p>
</div><h2>Take Control of Your Investment Journey</h2>
<div class="lb-trans"><h2>掌控您的投资旅程</h2>
</div><p>If United Therapeutics or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.</p>
<div class="lb-trans"><p>如果联合治疗公司或这些公司引起了您的关注，请免费注册 Simply Wall St，并将您的公司添加到观察列表中，以监控股价与公允价值的对比，并跟踪任何新动态。一旦您采取行动，使用我们的投资组合指挥中心管理您的持股，该中心过滤掉噪音，仅提供最关键、可操作的更新。在您的旅程中，我们的社区允许您从成千上万的投资者观点中筛选出最佳想法。通过及早发现隐藏的催化剂和风险，您将加快决策速度，始终领先于市场。</p>
</div><h2>Seeking Fresh Alternatives Before Others Catch On?</h2>
<div class="lb-trans"><h2>在别人注意到之前寻找新选择？</h2>
</div><p>Markets move fast and the best setups rarely stay quiet for long. To spot fresh momentum, potential breakouts, and stocks still flying under the radar for now, consider taking action while conditions remain favorable.</p>
<div class="lb-trans"><p>市场变化迅速，最佳的投资机会很少会保持安静。为了发现新的动能、潜在的突破以及目前仍在雷达下飞行的股票，请考虑在条件仍然有利时采取行动。</p>
</div><ul>
<li>Track sturdy earners with room to grow by scanning a curated list of solid balance sheet and fundamentals (45 results) that can help you avoid fragile stories before the cracks show.</li>
<li>Follow early strength in metal producers through a focused group of 34 elite gold producer stocks that may respond when sentiment shifts toward hard assets.</li>
<li>Monitor under-the-radar operators using a targeted pool of 22 high quality undiscovered gems before the broader market evaluates their cash flow and balance sheet quality.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过扫描一份经过筛选的稳健资产负债表和基本面（45 个结果），跟踪有成长空间的稳健盈利者，帮助您在裂痕显现之前避免脆弱的故事。</li>
<li>通过关注 34 只精英黄金生产股票，跟踪金属生产商的早期强劲表现，这些股票可能在市场情绪转向硬资产时作出反应。</li>
<li>使用一组 22 只高质量未被发现的潜力股，监控那些尚未被市场广泛评估现金流和资产负债表质量的低调运营商。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：在一个地方管理您的所有股票投资组合</strong></h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我们为股票投资者创建了 <strong>终极投资组合伴侣</strong>，<strong>而且是免费的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通过电子邮件或手机接收新的警告信号或风险提示</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟踪您股票的公允价值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免费试用演示投资组合</p>
</div>

3 Low Risk Leaders Powering AI, Pulmonary Drugs And Defense

- 三只低风险股票包括 Citizens Financial Group、United Therapeutics 和 Palantir Technologies。  
- 这些公司在不同领域具备稳健的资产负债表和较低的模型风险。  
- 文章提供了对股票筛选器的分析，适合风险厌恶型投资者。

Simplywall

三位低风险领导者正在推动人工智能、肺部药物和国防领域的发展